Sartorius Stedim Biotech S.A.

Factors to consider:

• Company pays dividends (annually): last record date 2025-04-03, amount 0.74$ (Y0.29%)
• Price in estimated range
• Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

• 2024-12-31 to 2025-12-31 estimated range: [150.36$, 255.57$]
• 2025-12-31 to 2026-12-31 estimated range: [153.66$, 261.53$]

Financial Metrics affecting the SDMHF estimates:

• Negative: with PPE of 101.9 at the end of fiscal year the price was very high
• Positive: 7.86 < Operating profit margin, % of 13.33
• Positive: -4.48 < Investing cash flow per share per price, % of -1.87
• Positive: Interest expense per share per price, % of 0.90 <= 3.41
• Positive: Inventory ratio change, % of -0.29 <= 0
• Negative: Industry earnings per price (median), % of 0 <= 0
• Negative: Industry operating cash flow per share per price (median), % of 0.78 <= 5.52